DFTX
Definium Therapeutics, Inc.NASDAQHEALTHCAREBIOTECHNOLOGY
Key Statistics
Market Cap
$2.63B
P/E Ratio
—
EPS
$-2.50
Beta
2.38
52W High
$26.25
52W Low
$6.34
50-Day MA
$22.24
200-Day MA
$15.91
Dividend Yield
—
Profit Margin
0.00%
Forward P/E
—
PEG Ratio
—
About Definium Therapeutics, Inc.
Definium Therapeutics, Inc., a clinical stage biopharmaceutical company, develops novel products to treat brain health disorders. The company is headquartered in New York, New York.
Fundamentals
| Revenue (TTM) | 0 |
| Gross Profit (TTM) | 0 |
| EBITDA | $-166.28M |
| Operating Margin | 0.00% |
| Return on Equity | -94.70% |
| Return on Assets | -35.70% |
| Revenue/Share (TTM) | $0.00 |
| Book Value | $2.68 |
| Price-to-Book | 9.43 |
| Price-to-Sales (TTM) | — |
| EV/Revenue | - |
| EV/EBITDA | — |
| Quarterly Earnings Growth (YoY) | 0.00% |
| Quarterly Revenue Growth (YoY) | 0.00% |
| Shares Outstanding | $109.07M |
| Float | $108.17M |
| % Insiders | 0.95% |
| % Institutions | 74.89% |
Historical Volatility
HV 10-Day
52.64%
HV 20-Day
52.36%
HV 30-Day
51.36%
HV 60-Day
54.27%
HV Rank
13.9%
Volatility is currently expanding
Analyst Ratings
Consensus ($39.87 target)
4
Strong Buy12
BuyMore HEALTHCARE Stocks
Data last updated: 6/13/2026